News

Cynata Therapeutics’ market-disruptive regenerative medicines complete world-first trial

Dr Killian Kelly, Cynata’s Vice President of Product Development spoke to Proactive Investors at the recent ASX Small and Mid-Cap Conference in Sydney

Read entire story